VNDA

Vanda Pharmaceuticals Stock Analysis

AI Rating

Fair
  • Quality4/10
  • Growth 2/10
  • Value 1/10
Vanda Pharmaceuticals sales and earnings growth
VNDA Growth
Fair
  • Revenue Y/Y 8.72%
  • EPS Y/Y -1033.33%
  • FCF Y/Y -579.76%
Vanda Pharmaceuticals gross and profit margin trends
VNDA Profitability
Fair
  • Gross margin 94.00%
  • EPS margin -102.00%
  • ROIC 5Y -10.28%
Vanda Pharmaceuticals net debt vs free cash flow
VNDA Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage 999.0

Vanda Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗